Use of dupilumab in patients with asthma in routine clinical practice: interim analysis of the international prospective REVEAL study in the Russian population

Aim. To assess the baseline characteristics of patients receiving dupilumab for asthma treatment in real-world setting. Materials and methods. This interim analysis included data from 74 patients aged ≥12 years across 6 Russian centers participating in the international prospective REVEAL study. Demographics, clinical characteristics, levels of T2 inflammatory biomarkers, lung function (FEV1), symptom control (ACQ-6), annualized exacerbation rates, T2 comorbidities, and healthcare resource utilization were assessed. Statistical analyses were performed using standard descriptive statistics. Results. The mean age of the patients was 47.8 years, 60.8% were women. Severe asthma (GINA stage 5) was present in 71.6%. At baseline, 74.3% had comorbid CRSwNP, 62.2% had AR, and 10.8% had AD. Dupilumab treatment resulted in significant reductions in median FeNO (-62.5% by month 3) and IgE (36.70 IU/mL by month 24). Lung function and asthma control improved (mean ACQ-6 reduction to 0.9 by month 24). Substantial decreases in exacerbation rates, hospitalizations, and emergency medical care were observed. Positive effects on T2 comorbidities were evidenced by improvements in SNOT-22, AR-VAS and POEM scores. Treatment-emergent adverse events occurred in 9.5% of patients, with only one patient discontinuing therapy. Conclusion. Dupilumab demonstrated high effectiveness and safety in the treatment of severe asthma in real-world setting, including improvement in symptom control, reduction in inflammatory markers and healthcare resource utilization. The results are consistent with data from randomized trials and confirm the feasibility of using dupilumab in patients with the T2 phenotype of asthma. This analysis is preliminary in nature, final conclusions will require study completion.